Valneva SE (VALN): Price and Financial Metrics
VALN Price/Volume Stats
| Current price | $7.47 | 52-week high | $17.05 |
| Prev. close | $7.55 | 52-week low | $6.58 |
| Day low | $7.47 | Volume | 319 |
| Day high | $7.47 | Avg. volume | 9,306 |
| 50-day MA | $7.65 | Dividend yield | N/A |
| 200-day MA | $10.83 | Market Cap | 520.20M |
VALN Stock Price Chart Interactive Chart >
Valneva SE (VALN) Company Bio
Valneva SE, a specialty vaccine company, focused on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; and DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium. The company also develops VLA15, a vaccine candidate that is in Phase II clinical trial against Borrelia; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; and VLA2001, a vaccine candidate that has completed Phase I/II clinical trial against SARS-CoV-2. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. The company has collaborations with Pfizer to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. Valneva SE was incorporated in 1999 and is headquartered in Saint-Herblain, France.
Latest VALN News From Around the Web
Below are the latest news stories about VALNEVA SE that investors may wish to consider to help them evaluate VALN as an investment opportunity.
Valneva Shareholders Approve EGM Resolutions Including the Transition to a Board of DirectorsAnne-Marie Graffin is appointed as Chair of the Board of Directors Saint-Herblain (France), December 20, 2023 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its shareholders approved the resolutions recommended by the Management Board at its Extraordinary General Meeting (EGM) held on December 20, 2023. These included the immediate transition from the Company’s two-tier governance model to a one-tier model led by a Board of Directors. During a |
VALNEVA Declaration of shares and voting rights - November 30, 2023VALNEVA Declaration of shares and voting rights November 30, 2023__________________________________________________________________________________________ Company name: VALNEVARegistered office: 6 rue Alain Bombard, 44800 Saint-Herblain (France)Regulated market of Euronext Paris - Compartment B Declaration date: December 6, 2023 Number of shares composing the share capital of ValnevaTotal number of voting rights including suspended voting rights*Description of the change Date on which this chan |
Pfizer, after delay, completes enrollment in Lyme vaccine trialThe announcement ends a lengthy setback that began when the company and partner Valneva accused a clinical trial site operator of study misconduct. |
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15 9,437* participants enrolled at sites across the U.S., Europe and Canada in areas where Lyme disease is endemic Trial conclusion expected by year-end 2025Pfizer aims to submit regulatory filings in the U.S. and Europe in 2026 New York, NY, and Saint-Herblain (France), December 4, 2023 – Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced that they have |
Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ®Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® Primary endpoint met with 97% seroresponse rate 24 months after a single vaccinationAntibody levels remained high and well above the seroresponse threshold, further supporting the anticipated long-term durability of the immune response No safety concerns identified in long-term follow up Saint-Herblain (France), December 4, 2023 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty |
VALN Price Returns
| 1-mo | -6.10% |
| 3-mo | -10.43% |
| 6-mo | -30.83% |
| 1-year | -21.46% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -27.96% |
| 2023 | -18.48% |
| 2022 | -77.09% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...